Connect with us


Pro Research: Wall Street dives into Amgen’s diverse biopharma strategies



Explore Wall Street’s expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring strategies that have outperformed the S&P 500 by up to 700%. This New Year, enjoy up to 50% off on a subscription to InvestingPro. In addition, take an extra 10% off a 2-year InvestingPro+ subscription with the code SFY24 or claim an extra 10% off a 1-year InvestingPro+ subscription with the code SFY241. To ensure ongoing access to valuable content like this, step up your investment game with InvestingPro.

In the ever-evolving landscape of biopharmaceuticals, Amgen Inc (NASDAQ:). stands out as a company with a keen focus on developing innovative therapies for serious illnesses. With a diverse portfolio that spans oncology, cardiovascular disease, bone health, neuroscience, nephrology, and inflammation, Amgen has been the subject of various Wall Street analyses over the past months, providing a wealth of insights into the company’s performance, strategy, and future outlook.

Company Overview and Performance

Amgen’s key assets, including Tarlatamab, AMG-193, BLINCYTO, Xaluritamig, LUMAKRAS, and Bemarituzumab, have positioned the company as a leader in immuno-oncology and precision oncology. The company’s pipeline progress, particularly post-ESMO presentations, has been acknowledged for its potential to revolutionize treatment in these fields. The Horizon transaction closure has further strengthened Amgen’s clinical progress narrative, adding notable assets like Tepezza, Krystexxa, and Uplizna to its portfolio.

The company’s financial results have been a mixed bag, with Q3 2023 earnings showing resilience in its base business, offsetting some underperformance in recent commercial launches. While revenues were in line with consensus, EPS outperformed expectations, hinting at a strong base despite challenges. Amgen’s updated FY23 guidance, which includes a significant increase in revenue and a slight increase in non-GAAP EPS, reflects the positive impact of the Horizon acquisition and provides clarity on pipeline positioning for the upcoming decade.

Market Trends and Competitive Landscape

Amgen’s strategic focus areas include the obesity program and the integration of Horizon’s assets, which have improved the company’s economics. The company has also been actively engaging with the FDA, particularly regarding tarlatamab, and has observed responses in lung cancer treatments involving PRMT5 inhibitors. Despite stiff competition in the Inflammation & Immunology (I&I) franchise and the NSCLC market, Amgen’s diversified oncology portfolio continues to show clinical progress.

The competitive landscape in biopharma is intense, with companies like Bristol Myers (NYSE:) Squibb gaining market enthusiasm for PRMT5 inhibitors. Amgen’s positioning in this environment is critical, with a need to maintain and grow its market share while navigating regulatory challenges and integrating new acquisitions successfully.

Financial Outlook and Projections

Analysts have provided various projections for Amgen’s financial performance. Revenue guidance for FY23 has been raised to between $28.0 billion and $28.4 billion, with non-GAAP EPS guidance also seeing an increase. Estimates for FY24 EPS and revenue have been revised upwards, reflecting optimism about the company’s growth potential. The closure of the Horizon transaction is expected to add significant value, potentially contributing an additional $6 billion in revenue by 2028.

Bear Case

Is Amgen’s base business decline a cause for concern?

Despite Amgen’s strong pipeline and recent acquisitions, there are concerns about the long-term stability of its revenue due to the decline in its base business. New product launches like Lumakras have underperformed, and there is persistent competition within the I&I franchise. The company’s size also makes significant organic growth challenging, though management’s conservative outlook post-merger may leave room for upside surprises.

Will regulatory challenges impede Amgen’s progress?

Regulatory hurdles, such as the FDA’s Complete Response Letter for Lumakras and the requirement for a new confirmatory study, could lead to delays and increased costs. The successful integration of Horizon and navigating the outcome of the transfer pricing case with the IRS are additional factors that could impact Amgen’s growth trajectory.

Bull Case

Can Amgen capitalize on its diversified oncology portfolio?

Analysts are optimistic about Amgen’s diversified oncology portfolio, which includes promising candidates like Tarlatamab and AMG-193. The company’s active engagement with the FDA and positive clinical trial results could lead to market enthusiasm and further development of these assets into earlier lines of therapy.

Will Amgen’s strategic acquisitions drive future growth?

The acquisition of Horizon Therapeutics (NASDAQ:) has been viewed positively, with expectations of significant revenue contribution. Amgen’s entry into the metabolic space with assets like AMG 133 and AMG 786 is seen as undervalued compared to competitors, offering a potential growth driver for the company.

SWOT Analysis


  • Diversified oncology portfolio with multiple assets showing clinical progress.
  • Strong pipeline with potential in oncology and obesity treatment areas.
  • Strategic acquisitions that could contribute to top-line growth.


  • Declining base business and underperformance of new product launches.
  • Regulatory challenges and successful integration of acquisitions remain critical.
  • Competition within the I&I franchise and pricing pressures.


  • Increased revenue guidance indicating growth potential from recent acquisitions.
  • Entry into the metabolic space with promising pipeline assets.
  • Expansion of market share in biopharmaceuticals through innovative therapies.


  • Risks associated with clinical trial outcomes and regulatory approvals.
  • Potential underperformance relative to sector due to valuation concerns.
  • Erosion of base business revenue if new products and acquisitions do not compensate adequately.

Analysts Targets

  • BMO Capital Markets: Outperform rating with a price target of $326.00 (December 19, 2023).
  • Barclays Capital Inc.: Underweight rating with a price target of $230.00 (December 27, 2023).
  • Truist Securities: Buy rating with a price target of $320.00 (November 2, 2023).

In conclusion, Amgen’s strategic maneuvers, diversified portfolio, and pipeline prospects offer a complex picture for investors. While the company faces challenges, including regulatory hurdles and competition, its recent acquisitions and focus on innovative therapies could propel it forward. The analyses span from October to December 2023, providing a comprehensive view of Amgen’s position in the biopharmaceutical industry.

InvestingPro Insights

As we delve into the financial nuances of Amgen Inc., it’s essential to consider up-to-date metrics and insights that could influence an investor’s perspective. Amgen has demonstrated a commitment to shareholder returns, as evidenced by its track record of raising dividends for 13 consecutive years, according to an InvestingPro Tip. This consistent increase in dividends underscores the company’s financial stability and its ability to generate sufficient cash flow.

Moreover, Amgen’s stock has shown low price volatility, another InvestingPro Tip that suggests the stock may be a suitable option for investors seeking stability in their portfolio. In terms of real-time data, Amgen boasts a market capitalization of $164.73 billion, reflecting its significant presence in the biotechnology industry. The company’s P/E ratio stands at 21.81, which, when compared to its near-term earnings growth, indicates that Amgen is trading at a high P/E ratio. Additionally, with a Price/Book ratio of 21.52 as of the last twelve months ending Q3 2023, the company is trading at a high multiple, which might be a point of consideration for value-focused investors.

It’s noteworthy that the InvestingPro platform offers a multitude of additional tips for Amgen, with over 10 insightful metrics available to subscribers. For those interested in gaining deeper insights, the InvestingPro subscription is now on a special New Year sale with a discount of up to 50%. To further sweeten the deal, use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Read the full article here